| About Us | Services | Experience | Our Team | Information | BioProcess Blog | Contact Us | Home |
EXPERTS TELL ALL
Opportunities in the Biosimilars Market
Patricia Seymour, Senior Consultant at BioProcess Technology Consultants, shares insight with Pharmaceutical Technology on the CMC challenges facing biosimilar developers.
Manufacturing and Regulatory Considerations in Biosimilars
Patti Seymour, Senior Consultant at BioProcess Technology Consultants, and other leading experts from a conference on biosimilars by the Drug, Chemical, and Associated Technologies Association, shared their insights on the manufacturing and regulatory considerations for biosimilars.
Biopharma CMOs see a rise in demand from pharmaceutical companies looking to cut costs
Patricia Seymour, Senior Consultant at BioProcess Technology Consultants, took a few minutes to share her views on the biologics CMO business with ICIS Chemical Business.
An Interview with James Blackwell, Ph.D., M.B.A., on QbD for Biopharmaceuticals
At Bioprocess International's 2009 conference, James Blackwell, Senior Consultant at BioProcess Technology Consultants, talked about QbD for smaller companies, and the importance of starting with the risk-management piece. Studying documented case studies from other industries can help professionals make a strong business case for QbD to senior management, he says.
Biosimilars, QbD Reshape the Biopharma Landscape: An Interview with Patricia Seymour
The Senior Consultant at BioProcess Technology Consultants took a few minutes to share her views on the forces driving biotech forward at BIO 2009.
Biosimilars Bet:
Merck uses new technology to enter nascent follow-on biologics market
Chemical & Engineering News, 87, pp. 28-29.
James Blackwell, Ph.D., M.B.A., Senior Consultant at BioProcess Technology Consultants, was interviewed by C&E News for this article on biosimilars (biogenerics) and Merck’s decision to enter the field with Merck BioVentures. The article discusses the current state of the field; Merck’s approach to the business, including its GlycoFi yeast expression technology; and regulatory and business drivers.
The Next Five Years—and More:
Bioindustry Leaders Weigh in on the Future
A group of experts were asked to predict what could happen in the next five years in the biopharmaceutical industry in a roundtable discussion. The discussion covered personalized medicine, PAT, disposables, downstream processing bottlenecks, CMOs, bi-fuels, stem cells, gene therapies and transgenics.
Click here for information about BioPharm International.
©Copyright 2009 BioProcess Technology Consultants, Inc.